PROJECT SUMMARY The LAO OH-007 UM1 research group consists of an experienced and innovative multi-disciplinary team of basic scientists and clinical investigators dedicated to finding effective new therapies for patients with cancer utilizing the resources available through CTEP NCI. The Ohio State University Comprehensive Cancer Center (OSUCCC) is a comprehensive biomedical research campus with strong collaborations between experienced investigators from multiple oncologic disciplines and a vibrant pattern of discovery in the basic sciences. The present consortium includes OSUCCC in collaboration with the University of Kentucky Markey Cancer Center (MCC) and the University of Utah Huntsman Cancer Institute (HCI) with whom they have had strong relationships in the past, and the University of North Carolina Lineberger Comprehensive Cancer Center (UNC LCCC) who joined LAO OH-007 one year ago. This application is being submitted to request additional funds for UNC, an Affiliated Organization to OSU, an ETCTN UM1 Lead Academic Organization. The funds will allow UNC to continue to participate in the ETCTN including leadership of two ETCTN studies led by Drs. Claire Dees and Joshua Zeidner (described in more detail below), continued accrual to ETCTN studies and participating in other activities including LOI submission and PTMA applications. The present proposal contains a request for funds to support the efforts of two research coordinators and two investigators. Going forward, there will be a continued concerted effort to incorporate the UNC LCCC group into the daily workings of its new home LAO so that study accrual and scientific discovery at this institution can be supported and enhanced. This consortium is committed to accruing a minimum of 100 patients per year to ETCTN studies and it is foreseen that the addition of the UNC LCC phase I group will contribute to this goal in a significant manner.